Pfizer (PFE) Inventory (2009 - 2026)

Pfizer (PFE) has reported Inventory for 18 consecutive years, with $9.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Inventory fell 14.77% year-over-year to $9.9 billion in Q2 2026; TTM through Jun 2026 was $9.9 billion, a 14.77% decrease from a year earlier, with the FY2025 full-year figure at $10.7 billion, down 1.82% from the prior year.
• Inventory was $9.9 billion for Q2 2026 at Pfizer, down from $10.7 billion in the prior quarter.
• Over five years, Inventory peaked at $11.7 billion in Q3 2024 and troughed at $9.0 billion in Q4 2022.
• A 5-year average of $10.6 billion and a median of $10.7 billion in 2025 frame the typical range for Inventory.
• Across the five-year window, Inventory advanced 17.5% in 2022 and declined 14.77% in 2026, its largest moves.
• Over 5 years, Inventory stood at $9.0 billion in 2022, then rose by 13.45% to $10.2 billion in 2023, then advanced by 6.5% to $10.9 billion in 2024, then fell by 1.82% to $10.7 billion in 2025, then slipped by 6.65% to $9.9 billion in 2026.
• The last three Inventory figures came in at $9.9 billion (Q2 2026), $10.7 billion (Q1 2026), and $10.7 billion (Q4 2025), per Business Quant data.